Parkinson’s disease is a progressive neurodegenerative disorder which results in depletion of dopamine within the substantia nigra pars compacta in the central nervous system.
Parkinson’s disease primarily affects the motor system causing the classical symptoms of bradykinesia, tremor and rigidity. In addition, Parkinson’s disease results in non-motor symptoms such as depression and dementia which can worsen over time.
The exact cause of Parkinson’s disease is unknown and there are no disease-modifying treatments. However, dopaminergic pharmacotherapies designed to restore depleted dopamine in the brain are the mainstay of treatment. These include levodopa, dopamine agonists and monoamine oxidase B (MAO-B) inhibitors.
As Parkinson’s disease progresses, motor complications emerge related to long-term symptomatic treatment. This requires more frequent dosing or the addition of other therapies, such as catechol-O-methyltransferase (COMT) inhibitors.
Related news and insights
AbbVie has announced that Vyalev (foslevodopa/foscarbidopa solution) is now available for the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper- /dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products
Amneal Pharmaceuticals announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX 203 versus optimized immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson’s disease (PD)